AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23221493 — intervention group
Group type: COMPARATOR
Intervention: Comments to the 'White' magazine
Number of subjects: 32
Study 21212502 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitching from a mound
Number of subjects: 17
Study 21212502 — intervention group
Group type: EXPERIMENTAL
Intervention: Throwing 37 m from flat ground
Number of subjects: 17
Study 21212502 — intervention group
Group type: EXPERIMENTAL
Intervention: Throwing 55 m from flat ground
Number of subjects: 17
Study 21212502 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum-distance throws
Number of subjects: 17
Study 21212502 — intervention group
Group type: EXPERIMENTAL
Intervention: Throwing distance increased
Number of subjects: 17
Study 18058852 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (mean dose 26.5 mg/day)
Number of subjects: 44
Study 18058852 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 16494565 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Imagery (GI) plus Usual Care
Number of subjects: 48
Study 16494565 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 48
Study 12626460 — intervention group
Group type: COMPARATOR
Intervention: RNase L 37-kDa/83-kDa ratio
Number of subjects: 11
Study 11088083 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical zanamivir (combined inhaled and intranasal zanamivir, inhaled zanamivir)
Number of subjects: 3815
Study 11088083 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3815
Study 11088083 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal and inhaled zanamivir
Number of subjects: 3815
Study 11088083 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled zanamivir
Number of subjects: 3815
Study 9052309 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined epidural/general anesthesia (Group I)
Number of subjects: 70
Study 9052309 — intervention group
Group type: COMPARATOR
Intervention: Inhaled anesthesia (Group II)
Number of subjects: 70
Study 1586184 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (12.5 mg/kg loading dose and 3 mg/kg daily maintenance)
Number of subjects: 44
Study 1586184 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (25 mg/kg loading and 6 mg/kg daily maintenance)
Number of subjects: 44
Study 1586184 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (7.5 mg/kg loading and 3 mg/kg thrice daily maintenance)
Number of subjects: 44
Study 2417075 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transhepatic placement of a permanent biliary endoprosthesis (PTE)
Number of subjects: 53
Study 2417075 — intervention group
Group type: COMPARATOR
Intervention: Bypass surgery
Number of subjects: 53
Study 30214183 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring (TM) including recording of symptoms, oxygen saturation, spirometry, and video consultations.
Number of subjects: 281
Study 30214183 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 281
Study 30214183 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring (TM) for patients with baseline 15D score <0.75
Number of subjects: 281
Study 30214183 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group) for patients with baseline 15D score <0.75
Number of subjects: 281
Study 30214183 — intervention group
Group type: COMPARATOR
Intervention: Telemonitoring (TM) and Usual care (control group)
Number of subjects: 281
Study 27347622 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous physical activity
Number of subjects: 64
Study 27347622 — intervention group
Group type: EXPERIMENTAL
Intervention: Open sub‐inguinal varicocelectomy (Group 1)
Number of subjects: 64
Study 27347622 — intervention group
Group type: EXPERIMENTAL
Intervention: Loupe‐assisted sub‐inguinal varicocelectomy (Group 2)
Number of subjects: 64
Study 27347622 — intervention group
Group type: EXPERIMENTAL
Intervention: Microscope‐assisted sub‐inguinal varicocelectomy (Group 3)
Number of subjects: 64
Study 23909452 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat 120 mg tid for 6 months
Number of subjects: 101
Study 23715201 — intervention group
Group type: EXPERIMENTAL
Intervention: ozonated olive oil and mineral wash
Number of subjects: 51
Study 23715201 — intervention group
Group type: EXPERIMENTAL
Intervention: placebo olive oil and mineral wash
Number of subjects: 51
Study 23715201 — intervention group
Group type: COMPARATOR
Intervention: ozonated olive oil
Number of subjects: 51
Study 23715201 — intervention group
Group type: COMPARATOR
Intervention: placebo olive oil only
Number of subjects: 51
Study 21168874 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone 150 mg + Dutasteride 0.25 mg
Number of subjects: 43
Study 21168874 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone 250 mg + Dutasteride 0.25 mg
Number of subjects: 43
Study 21168874 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone 400 mg + Dutasteride 0.25 mg
Number of subjects: 43
Study 21168874 — intervention group
Group type: COMPARATOR
Intervention: Testosterone 400 mg
Number of subjects: 43
Study 21168874 — intervention group
Group type: COMPARATOR
Intervention: Dutasteride 0.25 mg
Number of subjects: 43
Study 18346506 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm male subjects
Number of subjects: 29
Study 18346506 — intervention group
Group type: COMPARATOR
Intervention: Term male subjects
Number of subjects: 29
Study 17079759 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin plus CMF
Number of subjects: 2391
Study 17079759 — intervention group
Group type: COMPARATOR
Intervention: CMF alone
Number of subjects: 2391
Study 14566298 — intervention group
Group type: EXPERIMENTAL
Intervention: Newer Doppler diastolic function parameters
Number of subjects: 1012
Study 11063287 — intervention group
Group type: EXPERIMENTAL
Intervention: Network text analysis of bereavement advice
Number of subjects: 60
Study 8694310 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron 4 mg i.v.
Number of subjects: 161
Study 8694310 — intervention group
Group type: EXPERIMENTAL
Intervention: droperidol 0.65 mg i.v.
Number of subjects: 161
Study 8694310 — intervention group
Group type: EXPERIMENTAL
Intervention: droperidol 1.25 mg i.v.
Number of subjects: 161
Study 8694310 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 161
Study 8694310 — intervention group
Group type: EXPERIMENTAL
Intervention: droperidol 0.65 mg i.v. and 1.25 mg i.v.
Number of subjects: 161
Study 1357462 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohort nursing with gowns and gloves for all contacts of RSV-infected children
Number of subjects: 0
Study 1357462 — intervention group
Group type: COMPARATOR
Intervention: Gowns and gloves alone
Number of subjects: 0
Study 1357462 — intervention group
Group type: COMPARATOR
Intervention: Cohort nursing alone
Number of subjects: 0
Study 3440389 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactor intervention
Number of subjects: 12866
Study 3440389 — intervention group
Group type: COMPARATOR
Intervention: Cigarette smokers and blacks
Number of subjects: 12866
Study 30453660 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary fiber intake increased from 19 g/day to 29 g/day
Number of subjects: 32
Study 30453660 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary fiber intake increased
Number of subjects: 32
Study 27002500 — intervention group
Group type: EXPERIMENTAL
Intervention: HIVAX vaccine (replication-defective HIV-1 vaccine)
Number of subjects: 10
Study 27002500 — intervention group
Group type: EXPERIMENTAL
Intervention: HIVAX vaccine
Number of subjects: 10
Study 24457253 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotigotine
Number of subjects: 267
Study 24457253 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 267
Study 24457253 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analysis between UPDRS III and NMSS/PDSS-2 scores
Number of subjects: 267
Study 22203339 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor sleep (self-reported)
Number of subjects: 1362
Study 21226395 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-configuration suit
Number of subjects: 24
Study 21226395 — intervention group
Group type: COMPARATOR
Intervention: Half-configuration suit
Number of subjects: 24
Study 18479773 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical immunoassay for HBsAg detection
Number of subjects: 578
Study 18479773 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time PCR analysis for HBV DNA
Number of subjects: 578
Study 16641918 — intervention group
Group type: EXPERIMENTAL
Intervention: Chelation therapy with calcium disodium ethylenediaminetetraacetic acid (EDTA) weekly until body lead burden fell <60 microg for 3 months.
Number of subjects: 87
Study 16641918 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group) received weekly placebo for 3 months.
Number of subjects: 87
Study 16641918 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 87
Study 12737020 — intervention group
Group type: EXPERIMENTAL
Intervention: SMP + CaCO3
Number of subjects: 45
Study 12737020 — intervention group
Group type: COMPARATOR
Intervention: SMP + milk calcium
Number of subjects: 45
Study 11205774 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced HbA1 in non-diabetic stroke patients
Number of subjects: 59
Study 11205774 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormally high HbA1 and dFA in diabetics
Number of subjects: 59
Study 11205774 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting post-stroke glycaemia
Number of subjects: 59
Study 7752916 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN) with L-amino acid mixture, supplying 0.36 g N.kg‐1.d‐1
Number of subjects: 12
Study 2300922 — intervention group
Group type: EXPERIMENTAL
Intervention: High doses of methylprednisolone (HDC)
Number of subjects: 14
Study 2300922 — intervention group
Group type: COMPARATOR
Intervention: Nonsteroid treatment
Number of subjects: 14
Study 2300922 — intervention group
Group type: EXPERIMENTAL
Intervention: Total hip replacement (THR) surgery
Number of subjects: 14
Study 420261 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive teacher behavior
Number of subjects: 78
Study 420261 — intervention group
Group type: COMPARATOR
Intervention: Negative teacher behavior
Number of subjects: 78
Study 420261 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentally retarded label
Number of subjects: 78
Study 420261 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal label
Number of subjects: 78
Study 420261 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning-disabled label
Number of subjects: 78
Study 31794053 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS group
Number of subjects: 81
Study 31794053 — intervention group
Group type: COMPARATOR
Intervention: non-SMS group
Number of subjects: 81
Study 31292083 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-Based Education and Learning Program (HELP-AF) consisting of 2 home visits by a nurse or pharmacist trained in structured educational visiting (SEV) method.
Number of subjects: 620
Study 31292083 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 620
Study 31292083 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-Based Education and Learning Program (HELP-AF).
Number of subjects: 620
Study 28030741 — intervention group
Group type: EXPERIMENTAL
Intervention: Loving-kindness meditation
Number of subjects: 362
Study 28030741 — intervention group
Group type: EXPERIMENTAL
Intervention: Affect dyad
Number of subjects: 362
Study 28030741 — intervention group
Group type: EXPERIMENTAL
Intervention: Observing-thoughts meditation
Number of subjects: 362
Study 28030741 — intervention group
Group type: EXPERIMENTAL
Intervention: Perspective dyad
Number of subjects: 362
Study 28030741 — intervention group
Group type: COMPARATOR
Intervention: Retest control
Number of subjects: 362
Study 25862778 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehemodialysis
Number of subjects: 17
Study 25862778 — intervention group
Group type: EXPERIMENTAL
Intervention: Posthemodialysis
Number of subjects: 17
Study 25862778 — intervention group
Group type: COMPARATOR
Intervention: Participants without change in fluid overload
Number of subjects: 17
Study 25862778 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid overload
Number of subjects: 17
Study 23535358 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate immunization
Number of subjects: 79
Study 23535358 — intervention group
Group type: COMPARATOR
Intervention: Delayed immunization
Number of subjects: 79
Study 23535358 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugate vaccine
Number of subjects: 79
Study 23535358 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysaccharide vaccine
Number of subjects: 79
Study 22289557 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 μg/kg fentanyl bolus
Number of subjects: 800
Study 22289557 — intervention group
Group type: EXPERIMENTAL
Intervention: Priming dose of fentanyl 0.5 μg/kg followed by 1.5 μg/kg after 1 min
Number of subjects: 800
Study 22289557 — intervention group
Group type: EXPERIMENTAL
Intervention: Priming dose of fentanyl 0.5 μg/kg followed by 1.5 μg/kg after 2 min
Number of subjects: 800
Study 22289557 — intervention group
Group type: EXPERIMENTAL
Intervention: Priming dose of fentanyl 0.5 μg/kg followed by 1.5 μg/kg after 3 min
Number of subjects: 800
Study 22289557 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl priming dose
Number of subjects: 800
Study 22289557 — intervention group
Group type: EXPERIMENTAL
Intervention: Former smokers
Number of subjects: 800
Study 19023571 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive transforaminal lumbar interbody fusion (MITLIF)
Number of subjects: 36
Study 19023571 — intervention group
Group type: COMPARATOR
Intervention: Open midline transforaminal lumbar interbody fusion (TLIF)
Number of subjects: 36
Study 16757523 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinic acid treatment
Number of subjects: 45
Study 16757523 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 15282657 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-PF4/heparin antibodies
Number of subjects: 218
Study 15282657 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6
Number of subjects: 218
Study 11159092 — intervention group
Group type: EXPERIMENTAL
Intervention: Power injection through central venous catheter
Number of subjects: 225
Study 11159092 — intervention group
Group type: COMPARATOR
Intervention: Peripheral IV catheter
Number of subjects: 225
Study 9285658 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibutilide (0.01 then 0.002 mg/kg)
Number of subjects: 47
Study 9285658 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibutilide (0.02 then 0.004 mg/kg)
Number of subjects: 47
Study 9285658 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibutilide (0.03 then 0.006 mg/kg)
Number of subjects: 47
Study 9285658 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 7688253 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine ultrasonography in utero
Number of subjects: 2161
Study 7688253 — intervention group
Group type: COMPARATOR
Intervention: Control group (no routine ultrasonography)
Number of subjects: 2161
Study 3828181 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular timed injections of bupivacaine (0.5%, 0.375%, 0.25%)
Number of subjects: 240
Study 3828181 — intervention group
Group type: COMPARATOR
Intervention: On demand injections of bupivacaine (0.5%, 0.375%, 0.25%)
Number of subjects: 240
Study 3828181 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular top-up injections
Number of subjects: 240
Study 3828181 — intervention group
Group type: COMPARATOR
Intervention: On demand technique
Number of subjects: 240
Study 29508904 — intervention group
Group type: EXPERIMENTAL
Intervention: Low vitamin B12 status (<234 pmol/L; 317 pg/mL)
Number of subjects: 680
Study 29508904 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated homocysteine (>15 µmol/L)
Number of subjects: 680
Study 27269989 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial artery-specific Tiger catheter (5Fr; Terumo Interventional Systems)
Number of subjects: 110
Study 27269989 — intervention group
Group type: COMPARATOR
Intervention: Standard Judkins left and right catheters (5Fr R4, L4; Cordis Corporation)
Number of subjects: 110
Study 23394824 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive early-intervention programme
Number of subjects: 578
Study 23394824 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 578
Study 23948685 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive activity-based therapy applied during the critical period (younger than 2 years)
Number of subjects: 0
Study 23948685 — intervention group
Group type: COMPARATOR
Intervention: Previous activity-based therapies
Number of subjects: 0
Study 20036362 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary pain management programme
Number of subjects: 113
Study 20036362 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 113
Study 19069704 — intervention group
Group type: EXPERIMENTAL
Intervention: Open Milligan‐Morgan (MM) technique
Number of subjects: 63
Study 19069704 — intervention group
Group type: COMPARATOR
Intervention: Closed Ferguson (CF) technique
Number of subjects: 63
Study 16622438 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant oral capecitabine
Number of subjects: 0
Study 16622438 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant intravenous 5-FU/LV
Number of subjects: 0
Study 12630027 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon and amantadine hydrochloride (100 mg orally daily) for 26 weeks
Number of subjects: 31
Study 12630027 — intervention group
Group type: COMPARATOR
Intervention: Interferon alone (natural interferon‐beta 6 MU daily for 6 weeks and thrice‐a‐week for 20 weeks) for 26 weeks
Number of subjects: 31
Study 10492867 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (18-18+6 weeks)
Number of subjects: 1206
Study 10492867 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (20-20+6 weeks)
Number of subjects: 1206
Study 10492867 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3 (22-22+6 weeks)
Number of subjects: 1206
Study 8756814 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisone
Number of subjects: 27
Study 8756814 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 1673324 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol (less than or equal to 24 mg/min)
Number of subjects: 30
Study 1673324 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (less than or equal to 8 micrograms.kg‐1.min‐1)
Number of subjects: 30
Study 1673324 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane (less than or equal to 4%)
Number of subjects: 30
Study 7060824 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg triamcinolone hexacetonide (TH)
Number of subjects: 37
Study 7060824 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg methylprednisolone (MP)
Number of subjects: 37
Study 7060824 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 mg betamethasone (BM)
Number of subjects: 37
Study 30730159 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental Number Line Training (MNLT)
Number of subjects: 122
Study 30730159 — intervention group
Group type: COMPARATOR
Intervention: Arithmetic Training Active Control (ATAC)
Number of subjects: 122
Study 29297078 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensively hydrolyzed casein formula
Number of subjects: 2159
Study 29297078 — intervention group
Group type: COMPARATOR
Intervention: Conventional formula
Number of subjects: 2159
Study 26037723 — intervention group
Group type: COMPARATOR
Intervention: Discharge after 24 hours
Number of subjects: 2998
Study 26037723 — intervention group
Group type: EXPERIMENTAL
Intervention: Discharge after 72 hours
Number of subjects: 2998
Study 24369828 — intervention group
Group type: EXPERIMENTAL
Intervention: MUFA diet (35-45% of energy as fat; >20% as MUFA)
Number of subjects: 43
Study 24369828 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet (20-30% of energy as fat)
Number of subjects: 43
Study 24369828 — intervention group
Group type: COMPARATOR
Intervention: MUFA diet and Low-fat diet
Number of subjects: 43
Study 22413748 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir dipivoxil fumarate (test)
Number of subjects: 18
Study 19837534 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength Training (ST)
Number of subjects: 30
Study 19837534 — intervention group
Group type: COMPARATOR
Intervention: Walking Training (WT)
Number of subjects: 30
Study 18032264 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiential‐existential group psychotherapy
Number of subjects: 67
Study 18032264 — intervention group
Group type: COMPARATOR
Intervention: Social support group
Number of subjects: 67
Study 16170078 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human IL-1 receptor antagonist (rhIL-1ra)
Number of subjects: 34
Study 16170078 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 34
Study 12049374 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol or Propranolol (maximal tolerated dose, 28 patients, group A, 86±23 vs 98±29 mg/d)
Number of subjects: 56
Study 12049374 — intervention group
Group type: COMPARATOR
Intervention: No pharmacological therapy (28 patients, group B)
Number of subjects: 56
Study 12049374 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol or Propranolol (group A)
Number of subjects: 56
Study 12049374 — intervention group
Group type: COMPARATOR
Intervention: No pharmacological therapy (group B)
Number of subjects: 56
Study 12049374 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical therapy (beta-blockers)
Number of subjects: 56
Study 12049374 — intervention group
Group type: EXPERIMENTAL
Intervention: Head-up tilt test (HUT)
Number of subjects: 56
Study 9508205 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 3 mg i.v. plus dexamethasone 10 mg i.v. prechemotherapy followed by granisetron 1 mg orally at 6 and 12 hours, then granisetron 1 mg orally and dexamethasone 8 mg orally twice daily on days 2 through 7
Number of subjects: 435
Study 9508205 — intervention group
Group type: COMPARATOR
Intervention: Placebo substituted for granisetron on days 2 through 7
Number of subjects: 435
Study 7985177 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy with respiratory training mask
Number of subjects: 16